K-Beauty Money Has Moved From Brands Down to Manufacturing

What is the signal?

Macquarie PE, the private equity arm of Macquarie Asset Management, signed a share purchase agreement (SPA) with Affirma Capital on 18 September. What is being sold is roughly 70% of Hwasung Cosmetic and all of Nowcos, held by Affirma through the special purpose vehicle Asterion Holdings. On top of that, Macquarie PE is also acquiring the remaining 30% held by Hwasung Cosmetic founder Ryu Kyung-hoon and others. The total deal is reported at around KRW 300 billion, or roughly USD 216.6 million.

The two companies cover different ground. Hwasung Cosmetic is an ODM strong in color cosmetics such as eyebrow products, with global clients including L'Oréal and the Estée Lauder Companies alongside Korean indie brands. Last year it recorded revenue of KRW 110.7 billion and EBITDA of KRW 23.5 billion. Nowcos is an ODM centered on skincare. Securing both at once creates a production portfolio that runs from color through to skincare.

There was competition. A consortium of Korea Investment Private Equity and Ecopro, along with a European strategic investor, were in the running, and Macquarie PE took final negotiating rights. The definitive agreement came about a month after Macquarie was named preferred bidder in mid-August. Samsung Securities and Rothschild acted as sell-side advisors. Coverage read the deal as part of a shift in K-beauty investment away from brands and toward manufacturing and distribution infrastructure.

That said, this is the fact of a signed agreement and its terms, not a result. The deal value is a reported estimate of 'around KRW 300 billion', not a confirmed disclosed figure. Nothing has yet been made public about how production policy or the client mix at the two companies might change under the new owner. So this signal is better read not as an answer about the future of ODMs, but as the fact that what global capital is putting a price on in K-beauty has changed.

1. The price was attached to the makers, not the brand

For the past several years, the subject of most K-beauty investment stories was a brand. Which indie brand sold for how much, who took what share of the equity, was the news. The subject of this deal is not a brand but two ODMs. A manufacturer with KRW 110.7 billion in revenue, bundled with another manufacturer, was valued at around KRW 300 billion.

For anyone planning a brand, this shift touches the shape of the negotiation. Once a manufacturer becomes an asset that draws capital's attention, it also moves closer to being the party that chooses which clients to work with. Schedules and terms built on the assumption that there are plenty of places willing to make it may not pass as easily as they used to.

So what to review now is not the price sheet but the shape of the relationship. What kind of client we are to this manufacturer, and whether we are a predictable counterpart in volume, timing and information sharing, is what actually becomes leverage. Predictability lasts longer than the power to push a price down.

• Whether your core products are all concentrated with a single manufacturer
• Whether annual volume plans are shared with the manufacturer in advance
• Whether you have set out what you can offer beyond price

2. Why color and skincare were bundled together

The notable part of the deal's structure is that a color ODM and a skincare ODM were not bought separately but together. Hwasung Cosmetic is color, Nowcos is skincare. Combined, they become a portfolio that can serve both categories under one roof.

From a brand's side, this means the default of the manufacturing environment could change. Until now many brands have used different manufacturers by category, skincare with A, color with B. When one group holds both, the option of taking an entire line from a single place genuinely appears.

That option is not always the better one. Bundling simplifies communication and scheduling, but when something goes wrong at that one place, the whole line stops with it. What to bundle and what to split depends on a brand's scale and launch cadence. Writing down your answer now keeps you steady as the manufacturing landscape is reshaped.

3. What to check when a manufacturer changes hands

A private equity fund owning a manufacturer is not unusual in Korean cosmetics. This deal is structured the same way: a stake Affirma Capital held is passing to Macquarie PE. It is one fund handing over to another.

What a brand has to check in practice is not the ownership structure itself, but whether the parts that touch our work stay as they are. Whether the sales and R&D people assigned to us remain, whether the schedule and terms of in-flight development carry over, and how the formulas and specifications we handed across are managed, are where the real impact lands.

None of this appears in a press release. You have to ask, and you have to keep the answer in writing to be able to check it later. Rather than feeling uneasy at the news, it is more practical to gather the contacts and schedules for your in-flight projects and send one confirming email.

• Whether you have confirmed that contacts and schedules for in-flight development are unchanged
• Whether the contract covers storage and return of the formulas and specifications you provided
• Whether there is a notice procedure if production is discontinued or minimum order terms change

4. A global client list is a record, not equipment

Whenever coverage describes Hwasung Cosmetic, the client list is never left out. Names like L'Oréal and the Estée Lauder Companies appear alongside. That list raises the price not because the equipment is good, but because there is an accumulated record of having passed demands at that level.

Working with large global clients means quality documentation, raw material traceability, audit response and complaint handling all have to be maintained in a consistent form. That accumulation cannot be bought like a machine; it only appears with time. What capital put a price on is that time.

The same principle works on the brand side. For a brand heading into overseas distribution, the form in which your product's paperwork is kept becomes value later. Whether ingredient lists, test reports and stability data can be pulled out the moment they are needed is not only the manufacturer's problem.

5. Capacity expansion and acquisition point the same way

Across the Korean ODM sector this year, moves to expand capacity have continued. This time, capital moved toward buying an existing manufacturer instead. Building and buying are different methods, but they point the same direction. The ability to make cosmetics in Korea is itself being treated as a scarce resource.

Faced with a scarce resource, what a brand can do is get in line early. If a launch date is fixed, you have to work backwards from the production schedule to decide by when the formula must be locked. Production does not move forward by however much planning ran late.

Setting volume plans realistically is the same problem. When the minimum order quantity and the actual sales forecast diverge badly, you are left with stock or you miss the reorder window. The tighter the manufacturing environment gets, the more that divergence costs.

• Whether the formula lock date, worked backwards from the launch date, is written down
• Whether the minimum order quantity and the six-month sales forecast sit in the same table
• Whether you have confirmed the lead time for a reorder with the manufacturer

The first question for the brief

Write this on the first line of the brief: why would the place that makes this product still work with us on the same terms next year? In a market that puts a price on the makers, designing a reason to last with the place that makes it matters as much as designing a good product.